THERAKOS DEVELOPMENT
PharmaTHERAKOS DEVELOPMENT is a pharmaceutical company focused on Oncology.
THERAKOS DEVELOPMENT's Key Drugs
THERAKOS DEVELOPMENT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
THERAKOS DEVELOPMENT's Recent FDA Approvals
New NDA/BLA approvals for THERAKOS DEVELOPMENT over the last two years — novel drugs only, excluding generics and label supplements.
THERAKOS DEVELOPMENT's Therapeutic Areas
THERAKOS DEVELOPMENT's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
THERAKOS DEVELOPMENT's Top Competitors
THERAKOS DEVELOPMENT's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
THERAKOS DEVELOPMENT Pipeline Snapshot
Active clinical trials for THERAKOS DEVELOPMENT across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1999-02-25
- Latest
- 2021-03-19
- Applications
- 1